Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : HB2198
Therapeutic Area : Immunology
Study Phase : Preclinical
Recipient : Hinge Bio
Deal Size : $105.0 million
Deal Type : Collaboration
Hinge Bio Announces License and Collaboration with Kyorin Pharmaceutical
Details : The agreement aims for the development of Hinge’s multispecific antibody-based therapeutic HB2198 in Japan for Systemic Lupus Erythematosus.
Product Name : HB2198
Product Type : Antibody, Unconjugated
Upfront Cash : $10.0 million
September 30, 2025
Lead Product(s) : HB2198
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Recipient : Hinge Bio
Deal Size : $105.0 million
Deal Type : Collaboration
Lead Product(s) : KRP-M223
Therapeutic Area : Immunology
Study Phase : Preclinical
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Undisclosed
Deal Type : Licensing Agreement
KYORIN and Novartis Enter into a Global License Agreement for KRP-M223
Details : Under this agreement, KYORIN grants Novartis an exclusive worldwide license to develop, manufacture, and commercialize KRP-M223, an MRGPRX2 antagonist for allergic and inflammatory diseases.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
March 03, 2025
Lead Product(s) : KRP-M223
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Efzofitimod
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I
Recipient : aTyr Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Kyorin Holdings has initiated clinical development in Japan for aTyr’s lead therapeutic candidate ATYR1923 (known as KRP-R120 in Japan) following the Pharmaceutical and Medical Devices Agency (PMDA) review of its Clinical Trial Notification (CTN) submi...
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
August 11, 2020
Lead Product(s) : Efzofitimod
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Recipient : aTyr Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : OTO-6XX
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Preclinical
Sponsor : Otonomy
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Otonomy, entered exclusive license agreement with KYORIN Pharmaceutical that provides Otonomy with exclusive worldwide rights to develop, manufacture and commercialize a novel compound for the treatment of sensorineural hearing loss.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
August 03, 2020
Lead Product(s) : OTO-6XX
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Preclinical
Sponsor : Otonomy
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Reset All
